Neonc (NTHI) news
Recent news
Neonc Technologies appoints Ali Alabedin to its board of directors
AInvest Wire · 22h agoNeonc to meet FDA Nov. 17 on ne0212 phase 2 design
NeOnc Technologies Holdings, Inc. has scheduled a meeting with the U.S. Food and Drug Administration (FDA) on November 17, 2026, to discuss Phase 2 clinical trial design . The meeting is a key milestone in the company’s development timeline and will focus on the trial’s structure, endpoints, and…
AInvest Wire · Sep 29, 2026Neonc Technologies - FDA to hold end-of-phase 1 type B meeting with Neonc on Nov 17, 2026
AInvest Wire · Sep 29, 2026Neonc’s powerful brain cancer pipeline advances
NeOnc Technologies Holdings (NASDAQ: NTHI) is advancing its pipeline of therapies for central nervous system (CNS) cancers, with two programs in active development. The company is scheduled to meet with the U.S. Food and Drug Administration (FDA) on November 17, 2026, for an in-person End-of-Phase…
AInvest Wire · Sep 29, 2026Powerful Neonc brain cancer pipeline advances
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) has reported positive topline results from the Phase 2a portion of its clinical trial for NEO100™, an intranasal therapy for recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The study met its primary endpoint, with a six-month…
AInvest Wire · Sep 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.